| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Milestone Scientific, Inc.$0.4
+0.01 (+2.02%)
F 2Pipeline Score MedTech · Clinical
Market Cap
33.73 M
EPS
-0.06
P/E Ratio
-
Value Trade
26.91 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.16 M
Operating CF
86.84 K
Total Assets
7.96 M
Total Liabilities
5.68 M
Equity
2.28 M
D/E Ratio
12,345
14.33 %
Week
24.72 %
1 Month
45.41 %
3 Month
27.67 %
6 Month
-81.76 %
5 Year
-97.31 %
All Time
Cash Data
Cash Position
1.20 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
125.35 K
52 Week Range
0.22 - 1.01
% held by Insiders
16.48 %
% held by Institutions
5.06 %
Enterprise Value
33.52 M
Total Shares
80.44 M
Short %
0.25 %
Float Shares
66.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Milestone Scientific, Inc.
5Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 877 of 913)
Percentile RankMilestone Scientific, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MLSS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MLSS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MLSS▲ +5.3%on this news
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
Milestone Scientific has launched the first phase of its AI strategy with Milo, an AI-enabled digital engagement platform, at the ASPN Annual Conference. Milo is designed to enhance customer engagement and support commercial operations by providing immediate responses to inquiries and facilitating connections with sales and support teams. The platform will be piloted at the conference, with feedback guiding its future development.
Read more →MLSS▲ +9.2%on this news
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
Milestone Scientific Inc. reported preliminary revenue of approximately $2.8 million for Q2 2026, marking a 21% increase year-over-year. The company anticipates total revenue of around $5.0 million for the first half of 2026, reflecting a 9% growth compared to the same period in 2025. The medical segment is experiencing significant momentum, with a projected 300% growth compared to Q2 2025. The company will showcase its technology at the upcoming ASPN Conference in Miami Beach.
Read more →MLSSMilestone Scientific Strengthens Board to Support Next Phase of Growth
Milestone Scientific Inc. has announced significant governance changes to bolster its growth strategy. The company appointed Greg Shilling and Kelly Ann Ulto as independent directors, enhancing its Board's expertise. Benedetta I. Casamento has transitioned to Executive Chair, ensuring strategic continuity. Additionally, a restructured agreement with founder Len Osser aims to align governance with shareholder interests.
Read more →MLSSMilestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
Milestone Scientific Inc. has reported increasing clinical adoption of its CompuFlo Epidural System, backed by new research from the University of Texas Medical Branch. The study indicates that CompuFlo-guided procedures significantly reduce complication rates compared to traditional methods. This technology is gaining traction across various medical applications, enhancing safety and precision in epidural access.
Read more →MLSSMilestone Scientific Reports Financial Results for First Quarter 2026
Milestone Scientific reported financial results for Q1 2026, showing a reduced operating loss and a stable revenue base of $2.16 million. The company highlighted significant growth in its medical segment, with revenue doubling year-over-year. Despite challenges in shipping and a slight decrease in gross profit, management remains optimistic about achieving cash flow breakeven by early 2027.
Read more →MLSS▲ +9.3%on this news
Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
Milestone Scientific Inc. will hold a conference call on May 14, 2026, to discuss its financial results for Q1 2026 and corporate developments. The call aims to provide insights into the company's progress and future plans. Interested parties can access the call via telephone or a live webcast.
Read more →MLSS▲ +16.3%on this newsshared move
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
Milestone Scientific Inc. has expanded its CompuFlo® medical business through the Advisor Program, which has increased physician utilization and clinical engagement. The company is collaborating with academic institutions to support clinical validation and is enhancing its commercial infrastructure. However, the path to achieving Category I designation remains uncertain, dependent on sustained clinical utilization and peer-reviewed evidence.
Read more →MLSS▲ +8.7%on this news
Milestone Scientific Inc. Completes $2.15 Million Private Placement
Milestone Scientific Inc. has successfully completed a $2.15 million private placement of common stock and warrants, with potential for an additional $2.69 million if cash warrants are exercised. The CEO highlighted the financing as a means to strengthen the company's balance sheet and meet growing demand for its products. Participation from long-term investors underscores confidence in the company's technology and direction.
Read more →MLSS▲ +8.7%on this newsshared move
Milestone Scientific Inc. Completes $2.15 Million Private Placement Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board ROSEL
Milestone Scientific Inc. (NYSE: MLSS) completed a private placement financing of $2.15 million, enhancing its financial standing. This funding will support the company's growth strategy and consolidate its position in the market for computerized drug delivery instruments. The financing attracted long-term investors, including the CEO, underscoring a robust endorsement of the company's technology. However, the company faces uncertainties related to actual economic conditions and regulatory developments that could impact future performance.
Read more →MLSSMilestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
Milestone Scientific reported a modest revenue increase for Q4 2025 and a 4% rise for the full year, driven by international sales. The company anticipates significant growth in 2026, particularly with CompuFlo sales expected to rise by 400%. New leadership has focused on financial discipline and strategic investments to enhance growth prospects.
Read more →MLSS▼ -6.8%on this news
Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for April 1, 2026, to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call will also cover corporate progress and developments. Interested parties can join via telephone or access a webcast of the call.
Read more →MLSSMilestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
Milestone Scientific has launched the CompuFlo® Advisor Program aimed at boosting commercial adoption and generating clinical data for Medicare reimbursement. Targeting high-volume interventional pain and anesthesia practices, the program will initially focus on select MAC jurisdictions. The initiative includes engaging Key Opinion Leaders and plans for national expansion to enhance revenue visibility.
Read more →MLSSMilestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
Milestone Scientific has launched the CompuFlo® Advisor Program aimed at increasing commercial adoption and revenue growth in select Medicare jurisdictions. The initiative will involve engaging Key Opinion Leaders to submit cases and transition CPT® code 0777T to Category I status. The program is designed to support a scalable revenue model and facilitate national expansion.
Read more →MLSSMilestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
Milestone Scientific has launched The Wand® Ambassador Program aimed at enhancing the adoption of its Single Tooth Anesthesia System in dentistry. The program encourages peer-to-peer engagement among dental professionals to share insights and experiences. Following a successful pilot, Milestone plans to expand the program significantly over the next year, anticipating substantial growth in product demonstrations and sales conversions.
Read more →MLSSMilestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025
Milestone Scientific reported its third-quarter financial results for 2025, highlighting a reduction in operating expenses by over $500,000 and stable revenue of approximately $2.4 million. The company is focusing on growth initiatives, particularly in its dental segment and reimbursement strategies for its medical products. Despite a slight decrease in revenue compared to the previous year, the operational transformation is expected to enhance profitability and shareholder value.
Read more →MLSS▲ +6%on this newsshared move
Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. will host a conference call on November 14, 2025, to discuss its third quarter financial results and corporate developments. The call aims to provide insights into the company's progress and future direction. Stakeholders can participate via telephone or access a webcast of the event.
Read more →MLSSMonthly Info Drop: Edition 5
The article highlights the benefits of the Single-Tooth Injection for pediatric dental patients, emphasizing its comfort and lack of collateral numbness. It notes that this can lead to better patient experiences and increased referrals for dental practices. Additionally, it discusses the multi-cartridge feature that enhances efficiency in anesthetic delivery. The article encourages dentists to promote their services through social media and utilize new training resources.
Read more →MLSSMilestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Milestone Scientific Inc. has reported operational progress and growth initiatives under new CEO Eric Hines. The company has reduced operating expenses by 20% while achieving modest revenue growth. Hines has outlined strategies to enhance sales and marketing efforts, particularly in the dental and medical segments, and is optimistic about the company's future performance.
Read more →MLSSMilestone Scientific Commits to Regaining NYSE American Compliance Following Notification
Milestone Scientific Inc. has received a notification from NYSE American regarding non-compliance with listing standards due to insufficient stockholders' equity. The company reported approximately $3.3 million in equity and has experienced losses over the past five years. Milestone plans to submit a compliance plan by November 7, 2025, to address these issues and aims to regain compliance by April 8, 2027.
Read more →MLSSMonthly Info Drop: Edition 4
Milestone Scientific highlights the benefits of the Single-Tooth Injection with the STA, emphasizing its role in increasing dental practice efficiency and profitability. The article promotes upcoming webinars and training resources available to practitioners. Additionally, it encourages practices to inform patients about their commitment to comfort and care. The e-commerce site offers accessories for the STA system.
Read more →MLSSMilestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
Milestone Scientific has appointed Dr. Dawood Sayed to its Board of Directors to enhance its commercial and clinical strategies in pain management. Dr. Sayed, a prominent figure in interventional pain medicine, brings extensive experience and leadership in advancing innovative pain therapies. His appointment is expected to accelerate the adoption of Milestone's CompuFlo® Epidural System, which offers a safer alternative for spinal procedures.
Read more →MLSSMonthly Info Drop: Edition 3
The article highlights the advantages of using the Wand STA for palatal injections, emphasizing its virtually painless experience for patients and the absence of collateral numbness. It also provides maintenance tips for the STA device and promotes an upcoming webinar focused on enhancing patient experience in dental practices. Additionally, it encourages the use of new patient-facing brochures to improve communication about the Wand STA's benefits.
Read more →MLSS▲ +12.2%on this news
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
Milestone Scientific reported a 25% revenue increase to $2.3 million for Q2 2025, driven by strong international dental sales. The company appointed Eric Hines as CEO and Jason Papes as Senior VP of Sales and Marketing to enhance leadership. Despite revenue growth, Milestone faced operating and net losses, indicating challenges ahead.
Read more →MLSSMilestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for August 15, 2025, to discuss its financial results for Q2 2025 and corporate developments. The call will be accessible via telephone and webcast, allowing stakeholders to gain insights into the company's progress. An audio replay will be available until August 29, 2025.
Read more →MLSSMilestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing
Milestone Scientific has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of experience in healthcare sales and marketing, having previously led successful initiatives in various medical technology firms. His role will be crucial in advancing the commercial rollout of the CompuFlo Epidural System and enhancing the STA Single Tooth Anesthesia System's adoption.
Read more →MLSSObjective real-time epidural pressure measurement using the CompuFlo1 device, a mono-center observational study
The article discusses a mono-center observational study on the CompuFlo device, which measures epidural pressure in real-time. This innovative approach could enhance clinical practices and improve patient outcomes. Milestone Scientific reports a positive revenue growth and strengthening of its board, indicating a strategic focus on future growth.
Read more →MLSS▼ -10.5%on this newsshared move
Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer
Milestone Scientific has appointed Eric C. Hines as its new CEO, effective immediately. Hines brings over 25 years of leadership experience, particularly in scaling sales-driven companies. His appointment comes at a crucial time as the company aims to accelerate the adoption of its CompuFlo technology and expand into new markets. Recent reimbursement progress is seen as a strong foundation for future growth.
Read more →MLSS▼ -9.9%on this news· ran to -24% by day 3
Monthly Info Drop: Edition 2
The article highlights the benefits of the Wand STA system for dental injections, emphasizing the Bi-Rotational Insertion Technique that enhances patient comfort and accuracy. It also mentions the availability of different needle sizes for various injection needs. Upcoming events, including a webinar focused on improving patient experience, are announced, along with resources for dental practices.
Read more →MLSSMilestone Scientific Commences Sales of CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey
Milestone Scientific has begun commercial sales of its CompuFlo Epidural System at The Painless Center in Tenafly, New Jersey. Led by Dr. Chi-Shin Jason Chiu, the center aims to enhance patient safety and comfort through advanced technologies. The CompuFlo system utilizes proprietary technology to improve the accuracy of epidural injections, reflecting Milestone's commitment to innovation in pain management.
Read more →MLSSMilestone Scientific Commences Sales of CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey
Milestone Scientific Inc. has begun commercial sales of its CompuFlo Epidural System at The Painless Center in Tenafly, New Jersey. Led by Dr. Chi-Shin Jason Chiu, the center aims to enhance patient safety and comfort using this innovative technology. The CompuFlo system offers real-time feedback for accurate epidural procedures, reflecting Milestone's commitment to improving patient care.
Read more →MLSSMonthly Info Drop: Edition 1
The article provides tips for dental professionals on using the Wand Handpiece for injections, especially in sensitive cases. It emphasizes the capability of the STA technology for all types of dental injections and promotes upcoming events like the San Diego Dental Convention. Additionally, it highlights the success of the technology with over 100 million injections performed.
Read more →MLSS▲ +14.6%on this news
Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors
Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors, effective May 14, 2025. Thiyagalingam brings over 20 years of experience in the medical device and pharmaceutical sectors, focusing on commercial scaling and product innovation. His leadership is expected to support the company's strategy for expanding the adoption of its CompuFlo® Epidural System and enhancing commercial initiatives.
Read more →MLSSMilestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025
Milestone Scientific reported a revenue of $2.2 million for Q1 2025, reflecting a slight decrease from the previous year. The company noted positive developments in its medical segment, particularly with the CompuFlo® Epidural System, which is gaining traction among new practices. Despite an increase in operating losses, Milestone secured convertible financing to support its growth initiatives and is optimistic about expanding its market presence.
Read more →MLSSMilestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025
Milestone Scientific reported its financial results for 2024, showing a revenue decline to $8.6 million. However, the company is optimistic about 2025, citing strong initial performance and expansion of its CompuFlo® Epidural System. Significant progress has been made in establishing reimbursement frameworks, and e-commerce sales have improved. Despite challenges, Milestone is well-positioned for future growth.
Read more →MLSSMilestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey
Milestone Scientific has announced the incorporation of its CompuFlo® Epidural System at InfiniSurg, LLC in New Jersey. The system will be utilized by Dr. Roman Kosiborod, enhancing procedural safety and efficiency in epidural placements. This adoption reflects InfiniSurg's focus on innovative outpatient surgical care and Milestone's strategy to establish CompuFlo® as a standard in epidural procedures.
Read more →MLSS▲ +5%on this news
Milestone Scientific Expands Adoption of CompuFlo® Epidural System with Commercial Rollout at Pain Doctors Medical LLC
Milestone Scientific has successfully implemented its CompuFlo® Epidural System at Pain Doctors Medical LLC, enhancing patient safety and procedural efficiency. The system's real-time verification technology improves accuracy in epidural administration, as noted by Dr. Ilana Etelzon. This rollout follows recent Medicare pricing, which is expected to increase accessibility in pain management.
Read more →MLSS▲ +6.6%on this news
Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at Advanced Spine and Pain Management Following Successful Pilot with Dr. Varinder Dhillon
Milestone Scientific has announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management following a successful pilot program. The system, which utilizes patented Dynamic Pressure Sensing Technology®, aims to improve patient safety and procedural efficiency. The rollout is expected to expand within the SurgiCore network, driven by increasing adoption and favorable Medicare pricing.
Read more →MLSS▼ -7.2%on this news
Milestone Scientific to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference on December 11th, 2024
Milestone Scientific Inc. will present at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference on December 11, 2024. CEO Arjan Haverhals and Chairman Neal Goldman will engage in one-on-one meetings with investors at the event held in New York City. The conference aims to connect emerging growth companies with potential investors.
Read more →MLSS▲ +26.4%on this news
Milestone Scientific Secures Federal Supply Schedule (FSS) Approval on Contract for CompuFlo® Epidural System
Milestone Scientific has secured Federal Supply Schedule approval for its CompuFlo® Epidural System, allowing it to sell to government agencies. This contract enhances the company's market position and provides pre-negotiated pricing for federal healthcare systems. The technology aims to improve patient outcomes by ensuring accurate needle placement during epidural procedures.
Read more →MLSSMilestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024
Milestone Scientific reported a 22% increase in revenue for Q3 2024, reaching $2.5 million, driven by a 57% rise in international dental sales. The company is advancing the commercial rollout of its CompuFlo® Epidural System following Medicare price assignments. Despite the revenue growth, Milestone faced operating and net losses, highlighting ongoing challenges in international markets.
Read more →MLSSMilestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO
Milestone Scientific Inc. announced the retirement of CEO Arjan Haverhals, effective December 31, 2024. Neal Goldman, the Chairman of the Board, will serve as Interim CEO during the transition. The Board is actively seeking a permanent CEO to lead the company in its next growth phase, particularly focusing on the commercialization of the CompuFlo Epidural System.
Read more →MLSSMilestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for November 15, 2024, to discuss its third-quarter financial results and corporate developments. The call will be accessible via telephone and webcast, with a replay available until November 29, 2024. This event highlights the company's commitment to transparency and communication with stakeholders.
Read more →MLSSMilestone Scientific Expands Commercial Rollout of the CompuFlo® Epidural System with Esteemed Pain Management Physician Dr. Elbaz at Hudson Specialty Care
Milestone Scientific has announced the commercial rollout of its CompuFlo Epidural System at Hudson Specialty Care, led by Dr. Elbaz. This rollout follows a recent Medicare payment rate assignment, which is expected to increase access to the system. The company is also expanding its sales pipeline with pilot programs in multiple states and will participate in the upcoming Pain Medicine Congress.
Read more →MLSSMilestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at iHeal Pain Center Following Medicare Price Assignment
Milestone Scientific has announced the commercial rollout of its CompuFlo® Epidural System at iHeal Pain Center, following successful procedures by Dr. Desai. This rollout comes after the system received a favorable Medicare payment rate, enhancing its adoption across multiple states. The partnership with Axial Biologics is expected to further accelerate the system's integration in clinics.
Read more →MLSSMilestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024
Milestone Scientific reported a positive business update for Q2 2024, highlighting a Medicare price assignment for its CompuFlo® Epidural System and a significant increase in gross margins driven by e-commerce sales. The company formed a strategic partnership with Axial Biologics to enhance its market presence. However, international revenue faced challenges, and overall revenue decreased compared to the previous year.
Read more →MLSS▲ +5.2%on this newsshared move
Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call
Milestone Scientific Inc. will hold a conference call on August 15, 2024, to discuss its financial results for Q2 2024 and corporate developments. The call will be accessible via telephone and webcast, with an audio replay available until August 29, 2024. This event highlights the company's commitment to keeping investors informed.
Read more →MLSS▲ +7.7%on this newsshared move
Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida
Milestone Scientific has formed a strategic partnership with Axial Biologics to distribute its CompuFlo® Epidural System in New Jersey, Texas, and Florida. This collaboration follows the recent Medicare Part B payment rate assignment for the system, which is expected to enhance its adoption in the pain management community. The partnership aims to leverage Axial's established relationships to accelerate market penetration and improve patient outcomes.
Read more →MLSSMilestone Scientific Secures Key Patent Approvals in the U.S. and Europe
Milestone Scientific has announced the receipt of multiple Notices of Allowance for essential patent applications in the U.S. and Europe. These patents cover their innovative Dynamic Pressure Sensing technology, which improves the accuracy and safety of manual injections. The CEO emphasized that these advancements strengthen their market leadership and open new opportunities for their technology.
Read more →MLSSLoss-of-Resistance Versus Dynamic Pressure-Sensing Technology for Successful Placement of Thoracic Epidural Catheters: A Randomized Clinical Trial
The article discusses a randomized clinical trial comparing loss-of-resistance and dynamic pressure-sensing technology for the placement of thoracic epidural catheters. The trial aims to evaluate the effectiveness and safety of these methods. Preliminary results suggest positive outcomes for the dynamic pressure-sensing approach, highlighting its potential in clinical practice.
Read more →MLSSFollowing Successful FDA Marketing Clearance of the CompuFlo Epidural Instrument, Milestone Scientific Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company Leonard
Following Successful FDA Marketing Clearance of the CompuFlo Epidural Instrument, Milestone Scientific Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company Leonard Osser to Continue as Director of China Operations and a Boa
Read more →MLSSDavid Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020 MILESTONE SCIENTIFIC ANNOUNCES 510(k) FDA CLEARANCE FOR COMPUFLO EPIDURAL INSTRUMENT LIVINGSTON, NJ, J
David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com MILESTONE SCIENTIFIC ANNOUNCES 510(k) FDA CLEARANCE FOR COMPUFLO EPIDURAL INSTRUMENT LIVINGSTON, NJ, June 12, 2017 -- Milestone Scientific Inc. (NYSE: MLSS) today announced that the Co
Read more →MLSSDavid Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020 MILESTONE SCIENTIFIC INC. PRICES PUBLIC OFFERING OF COMMON STOCK AND WARRANTS FOR GROSS PROCEEDS OF $3
David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com MILESTONE SCIENTIFIC INC. PRICES PUBLIC OFFERING OF COMMON STOCK AND WARRANTS FOR GROSS PROCEEDS OF $3 MILLION LIVINGSTON, NJ, December 16, 2016 -- Milestone Scientific Inc. (NYSE MKT:
Read more →MLSSDavid Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020 Milestone Scientific, Inc. Announces Exclusive Distribution Agreement with Henry Schein, Inc. Distribu
David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Milestone Scientific, Inc. Announces Exclusive Distribution Agreement with Henry Schein, Inc. Distribution Agreement Includes Dedicated Specialty Sales Force and Guaranteed Minimums
Read more →MLSSInvestor Relations: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020 Milestone Scientific Appoints Gian Domenico Trombetta as President & CEO of its Dental Divi
David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Milestone Scientific Appoints Gian Domenico Trombetta as President & CEO of its Dental Division Joins Milestone Scientific Board of Directors LIVINGSTON, NJ, May 27, 2014 Milestone Sci
Read more →MLSSMILESTONE SCIENTIFIC AND TRI-ANIM HEALTH SERVICES FORM STRATEGIC PARTNERSHIP TO INTRODUCE PRECISION INJECTION TECHNOLOGY Tri-anim to be Distributor of Milestone s Epidural Injection Technology for Childbirth and Other Pa
MILESTONE SCIENTIFIC AND TRI-ANIM HEALTH SERVICES FORM STRATEGIC PARTNERSHIP TO INTRODUCE PRECISION INJECTION TECHNOLOGY Tri-anim to be Distributor of Milestone s Epidural Injection Technology for Childbirth and Other Pain Management LIVINGSTON, NJ July, 9, 2013 Milestone Sci
Read more →MLSSMILESTONE SCIENTIFIC ANNOUNCES KEY LEADERSHIP CHANGES Director Leslie Bernhard Appointed as New Chairman and Leonard Osser Resumes Full Duties and Responsibilities as CEO PISCATAWAY, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC ANNOUNCES KEY LEADERSHIP CHANGES Director Leslie Bernhard Appointed as New Chairman and Leonard Osser Resumes Full Duties and Responsibilities as CEO PISCATAWAY, N.J. (PR NEWSWIRE) September 1, 2009 Milestone Scientific Inc. (OTCBB:MLSS), the recognized le
Read more →MLSSMILESTONE SCIENTIFIC ACQUIRES ADDITIONAL PATENT RIGHTS FOR PAINLESS INJECTIONS AND RESOLVES RELATED LITIGATIONS LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC ACQUIRES ADDITIONAL PATENT RIGHTS FOR PAINLESS INJECTIONS AND RESOLVES RELATED LIVINGSTON, N.J. (PR NEWSWIRE) October 2, 2008 Milestone Scientific Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced that it has acqu
Read more →MLSSMILESTONE SCIENTIFIC EXPANDS U.S. AND CANADIAN DISTRIBUTION NETWORK WITH ADDITION OF PATTERSON DENTAL SUPPLY LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC EXPANDS U.S. AND CANADIAN DISTRIBUTION NETWORK WITH ADDITION OF PATTERSON DENTAL SUPPLY LIVINGSTON, N.J. (PR NEWSWIRE) June 5, 2008 Milestone Scientific Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced that it ha
Read more →MLSSMILESTONE SCIENTIFIC NAMES JOSEPH D AGOSTINO AS ACTING CHIEF FINANCIAL OFFICER LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC NAMES JOSEPH D AGOSTINO AS ACTING CHIEF FINANCIAL OFFICER LIVINGSTON, N.J. (PR NEWSWIRE) January 30, 2008 - Milestone Scientific Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced that Joseph D Agostino, CPA, has
Read more →MLSSMILESTONE SCIENTIFIC COMMENCES DECLARATORY JUDGMENT ACTION WITH RESPECT TO ITS SINGLE TOOTH ANESTHESIA (STA ) SYSTEM AND COMPUDENT SYSTEM Defendant Brings Infringement Action LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC COMMENCES DECLARATORY JUDGMENT ACTION WITH RESPECT TO ITS SINGLE TOOTH ANESTHESIA (STA ) SYSTEM AND COMPUDENT SYSTEM Defendant Brings Infringement Action LIVINGSTON, N.J. (PR NEWSWIRE) September 12, 2007 Milestone Scientific, Inc. (OTCBB:MLSS) today anno
Read more →MLSSMILESTONE SCIENTIFIC ANNOUNCES APPOINTMENT OF ACTING CHIEF FINANCIAL OFFICER LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC ANNOUNCES APPOINTMENT OF ACTING CHIEF FINANCIAL OFFICER LIVINGSTON, N.J. (PR NEWSWIRE) August 22, 2007 Milestone Scientific, Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced the appointment of Arthur Goldberg, C
Read more →MLSSMILESTONE SCIENTIFIC SECURES $1 MILLION REVOLVING LINE OF CREDIT LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC SECURES $1 MILLION REVOLVING LINE OF CREDIT LIVINGSTON, N.J. (PR NEWSWIRE) July 9, 2007 Milestone Scientific, Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced that it has secured a $1 million revolving line of c
Read more →MLSSMILESTONE SCIENTIFIC ANNOUNCES PLANS TO APPOINT NEW CHIEF FINANCIAL OFFICER Current CFO to Resign to Pursue New Career Opportunities LIVINGSTON, N.J. (PR NEWSWIRE)
MILESTONE SCIENTIFIC ANNOUNCES PLANS TO APPOINT NEW CHIEF FINANCIAL OFFICER Current CFO to Resign to Pursue New Career Opportunities LIVINGSTON, N.J. (PR NEWSWIRE) June 25, 2007 Milestone Scientific, Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies,
Read more →MLSSLeonard Osser, Chairman and CEO Stuart J. Wildhorn President Milestone Scientific Inc. (973) 535-2717; (973) 535-2829 (Fax) Web site: www.milesci.com MILESTONE SCIENTIFIC, INC. ANNOUNCES YEA
Leonard Osser, Chairman and Stuart J. Wildhorn President Milestone Scientific Inc. (973) 535-2717; (973) Web site: www.milesci.com MILESTONE SCIENTIFIC, INC. ANNOUNCES YEAR END RESULTS, INCLUDING 20% REVENUE INCREASE AND IMPROVED FINANCIAL POSITION LIVINGSTON, New Jersey, A
Read more →MLSSd61801_ex99-1.txt PRESS RELEASE FOR IMMEDIATE RELEASE CONTACT Stuart Wildhorn, President Milestone Scientific Inc (973) 535-2717; (973) 535-2829 (Fax) Web site: www.milesci.com MILESTONE SCIENTIFIC INC. TO SUBMIT CONTINU
Stuart Wildhorn, President Milestone Scientific Inc (973) 535-2717; (973) 535-2829 (Fax) Web site: www.milesci.com MILESTONE SCIENTIFIC INC. TO SUBMIT CONTINUED LISTING COMPLIANCE PLAN TO AMERICAN STOCK EXCHANGE LIVINGSTON, New Jersey, January 5, 2004 -- Milestone Scientifi
Read more →Competitive Position
How MLSS ranks across every disease it competes inCompetitive Position is a premium feature
See how MLSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial